Pfizer said revenue for Q1 2026 was $14,451 million, up 5% from $13,715 million a year earlier (2% on an operational basis). The company said that excluding contributions from Comirnaty and Paxlovid, revenue grew 7% on an operational basis.

1. 01

   Pfizer said revenue for Q1 2026 was $14,451 million, up 5% from $13,715 million a year earlier (2% on an operational basis). The company said that excluding contributions from Comirnaty and Paxlovid, revenue grew 7% on an operational basis.

2. 02

   The company said Reported net income for Q1 fell 9% to $2,687 million, and Reported diluted EPS was $0.47. It said Adjusted income was $4,290 million and Adjusted diluted EPS was $0.75, with both down 18%.

3. 03

   The company reaffirmed its full-year 2026 outlook (guidance), with revenue of $59.5 billion to $62.5 billion and Adjusted diluted EPS of $2.80 to $3.00. It said the outlook does not assume any share repurchases in 2026.

4. 04

   The company said that in the first 3 months of 2026 it invested $2.5 billion in internal R&D projects and about $110 million in business development transactions, and paid $2.4 billion in cash dividends ($0.43 per share).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.